Pharming GroupPHAR +0.53%79 FCF Yield % is 5.91 as of Jun. 26, 2026, which is 72% above its 10-year median of 3.44. GuruFocus rates PHAR with a GF Score™ of 79/100 and a GF Value™ of $14.28 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, Pharming Group ranks better than 94.43% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Pharming Group FCF Yield % Related Terms
Pharming Group FCF Yield % Historical Data
* Premium members only.
The historical data trend for Pharming Group's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharming Group's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Pharming Group's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (PHAR) has a FCF Yield % of 5.91 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pharming Group and its competitors. This is 72% above median its historical median of 3.44. According to the industry distribution chart, Pharming Group ranks #79 out of 1418 companies in the Biotechnology industry, placing it in the top 5.6%.
Is Pharming Group's FCF Yield % too high?
Pharming Group's current FCF Yield % of 5.91 is 72% above median its 10-year median of 3.44. Based on the distribution chart, Pharming Group ranks #79 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #79 out of 1418 companies for FCF Yield %. This places Pharming Group in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pharming Group and its competitors. Pharming Group's current FCF Yield % is 5.91, which is 72% above median its own 10-year median of 3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.28, compared to a current price of $13.34 — trading 6.6% below its estimated fair value. The current FCF Yield % is 5.91, which is 72% above median its 10-year median of 3.44. Pharming Group's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Pharming Group (PHAR), the current FCF Yield % is 5.91 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.34 is trading 6.6% below its estimated GF Value™ of $14.28.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
FCF Yield %: 5.91 (72% above median its 10-year median of 3.44)
GF Value™: $14.28 vs. price of $13.34 (6.6% below fair value)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score
Get the complete analysis for PHAR
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
